Sildenafil Citrate
Product Images NDC 50436-0295

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 50436-0295). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl504360295)

This is a prescription drug with NDC number 50436-0295-1 named Sildenafil. The tablet contains 20mg of Sildenafil. The rest of the text is not readable and appears to be random characters and symbols.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 06)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 07)

This document appears to be a chart of drug interactions and recommendations for dose adjustments based on the fold change and 90% confidence interval. The drugs listed include Acitomycin, Bosentan, Cimetidines, Evomyeint, Maslox, Oral Contraceptives, Rionavit, and Sapionis K8. The chart also includes a reference to changes relative to Sildenafil alone and a note that there is no benefit to exercise capacity when Sildenafil is added to bosentan therapy.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 08)

This text describes the interactions of various drugs with Acenocoumarol. The table provides information about the fold change, the recommended dose adjustment, and the relative change of interacting drugs. The study concludes that there is no benefit on exercise capacity when sildenafil is added to bosentan therapy. However, it is not recommended to co-administer sildenafil with ritonavir based on the effect of ritonavir on sildenafil PK.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 09)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 10)

This appears to be a table or report related to a clinical study on the effects of a drug on patients with idiopathic pulmonary arterial hypertension (PAH). The drug being tested is either Placebo or Sildenafil 20mg TID. The report includes information on the patients' age, gender, walk distance, and pulmonary arterial pressure. There is also a graph showing the change in 6-minute walk distance over time. However, there is not enough information to determine the full details or outcomes of the study.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 11)

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 12)

The text describes the changes in meters from baseline for different treatments (Sildenafil 1mg, 5mg, and 20mg taken at different times) at different weeks of a study (up to week 12). The plot represents the mean change from baseline with the Standard Error for each treatment at each visit.*

FDA Label Image

Structure Formula (Sildenafil Tablets Usp 20mg Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.